Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a sell rating to a hold rating in a report released on Monday.

According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. “

Several other analysts have also issued reports on BIOC. ValuEngine raised Biocept from a sell rating to a hold rating in a report on Friday, June 1st. Westpark Capital lowered Biocept from an outperform rating to a hold rating in a report on Wednesday, May 23rd.

Shares of BIOC opened at $3.05 on Monday. Biocept has a one year low of $2.86 and a one year high of $40.50. The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42.

Biocept (NASDAQ:BIOC) last released its quarterly earnings results on Tuesday, August 14th. The medical research company reported ($2.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.30) by $0.60. Biocept had a negative return on equity of 587.80% and a negative net margin of 642.49%. The business had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.09 million. research analysts predict that Biocept will post -9.01 EPS for the current fiscal year.

An institutional investor recently raised its position in Biocept stock. BlackRock Inc. raised its stake in shares of Biocept Inc (NASDAQ:BIOC) by 1.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 794,302 shares of the medical research company’s stock after purchasing an additional 14,403 shares during the period. BlackRock Inc. owned 34.99% of Biocept worth $159,000 as of its most recent SEC filing.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.